Vivesto AB ADR ( (OASMY) ) has released its Q1 earnings. Here is a breakdown of the information Vivesto AB ADR presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vivesto AB is a Swedish development company focused on creating new treatment options for difficult-to-treat cancers, with a portfolio that includes the Cantrixil cancer program for blood cancer and the Paccal Vet program for veterinary oncology.
In the first quarter of 2025, Vivesto AB reported significant progress in its development programs, including regulatory advancements, strategic agreements, and the acquisition of global rights to Cantrixil. The company aims to become a leading oncology-focused development firm.
Key highlights from the quarter include the conversion of an option agreement with Zhejiang Zhida Pharmaceutical Ltd into a full license agreement for Apealea, securing a $250,000 upfront payment and potential milestone payments up to $5.6 million. Additionally, Vivesto acquired global rights to Cantrixil from Kazia Therapeutics for $1 million, eliminating future obligations such as milestone payments and royalties.
Financially, the company reported a net revenue of 0 and an operating loss of -8,588 thousand SEK for the quarter. Despite the financial losses, Vivesto’s strategic moves, such as securing a credit facility with its main owner Arwidsro, are expected to support its operations into 2026.
Looking ahead, Vivesto’s management remains optimistic about achieving key milestones in 2025, which could significantly impact patients in need of new treatments and benefit shareholders. The company continues to explore partnerships to optimize and accelerate its programs.